Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology pipeline includes off-the-shelf, iPSC-derived natural killer (NK) cell and T-cell product candidates, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens using chimeric antigen receptors (CARs). Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Location: United States, California, San Diego
Founded date: 2007
Investors 2
| Date | Name | Website |
| 17.07.2021 | ARCH Ventu... | archventur... |
| 12.07.2023 | Johns Hopk... | ventures.j... |
Mentions in press and media 25
| Date | Title | Description | Source |
| 05.03.2024 | Fate Therapeutics Reports New Employee Inducement Award Unde... | - | globenewsw... |
| 28.02.2023 | Fate Therapeutics Reports Fourth Quarter and Full Year 2022 ... | /EIN News/ -- Ended 2022 with Approximately $475 Million in Cash, Cash Equivalents, and Receivables ... | einpresswi... |
| 06.01.2023 | Fate Stock Sinks. Analysts Downgrade Shares on End to Jansse... | Fate Therapeutics was sinking Friday as analysts downgraded shares of the stem-cell company after it... | barrons.co... |
| 05.01.2023 | Fate Therapeutics Announces Termination of Collaboration Agr... | /EIN News/ -- Ended 2022 with Approximately $475 Million in Cash, Cash Equivalents & Receivables... | einpresswi... |
| 05.01.2023 | Fate Therapeutics plans mass layoffs, after early end to cel... | SAN DIEGO — Fate Therapeutics, a biotech upstart with big ambitions to use cell-based therapies to t... | statnews.c... |
| 22.08.2021 | Anti-aging research foundation sacks CSO Aubrey de Grey... | Caught in the center of a boiling controversy over accusations of sexual harassment lev... | endpts.com... |
| 20.08.2021 | Insilico finds a new partner for AI drug discovery; EU... | MIT star researcher and CRISPR pioneer Feng Zhang put a new paper out Thursday in Science detailing ... | endpts.com... |
| 19.08.2021 | Fate's closely watched stem cell-derived NK program rais... | At the cutting edge of oncology research, biotechs like Fate Therapeutics are looking for w... | endpts.com... |
| 26.03.2021 | Merck keeps it in the family as Robert Davis hands the CF... | Caroline Litchfield → With Robert Davis preparing to take over as Merck’s CEO, the Big Pharma ... | endpts.com... |
| 13.02.2021 | Another Keytruda combo tops standard of care in advanc... | Late last summer, one of the earliest stem cell therapy companies got two government decisions in th... | endpts.com... |
Show more